Overview

TPI 287 in Patients With Recurrent Glioblastoma Multiforme

Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if TPI 287 can help to control glioblastoma. The safety of this drug will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Cortice Biosciences, Inc.
Treatments:
Temozolomide